{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:06:28Z","timestamp":1791428788389,"version":"4.3.3"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014421","name":"EA Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014421","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background\/Aims<\/jats:title>\n                  <jats:p>With the recent increase in available treatment options for inflammatory bowel disease (IBD), shared decision-making has gained considerable importance. To address potential disparities in patient and physician priorities, we conducted a survey to clarify these perspectives.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with IBD and physicians treating IBD were asked to complete an online questionnaire focused on key factors influencing drug selection and preferred drug administration methods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Responses were obtained from 400 patients (327 with ulcerative colitis and 73 with Crohn\u2019s disease) and 155 physicians. Among the factors in drug selection, physicians assigned significantly higher importance scores for experience with the drug than did patients. The expected time to onset of drug effects was significantly different between patients and physicians. Regarding preferences for drug administration method, patients and physicians assigned the highest acceptability scores for once-daily oral administration. For intravenous and subcutaneous routes, patients\u2019 scores were significantly lower than those of physicians\u2019 scores. Notably, 86.0% of patients and 62.0% of physicians preferred oral administration as the most preferred method. However, preferences varied based on treatment experience: 34.7% of patients with prior experience with subcutaneous injection preferred this method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients and physicians generally shared similar priorities for drug selection; however, physicians emphasized their experience with the drug over patient preferences. Although the number of patients with prior treatment experience preferred intravenous or subcutaneous injections, oral formulations remained the preferred choice for both patients and physicians.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otaf014","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T11:12:44Z","timestamp":1744197164000},"source":"Crossref","is-referenced-by-count":4,"title":["Questionnaire Survey of Japanese Patients With Inflammatory Bowel Disease and Physicians on Shared Decision-Making in Advanced Therapy: A Web-Based PAIR Survey"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5493-5675","authenticated-orcid":false,"given":"Fumihito","family":"Hirai","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Fukuoka University , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9786-3854","authenticated-orcid":false,"given":"Takayuki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University , Iwate ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7472-6160","authenticated-orcid":false,"given":"Keita","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of IBD Strategy, EA Pharma Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0227-115X","authenticated-orcid":false,"given":"Yuki","family":"Goda","sequence":"additional","affiliation":[{"name":"Department of IBD Strategy, EA Pharma Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6207-4843","authenticated-orcid":false,"given":"Yuki","family":"Fujimitsu","sequence":"additional","affiliation":[{"name":"Department of IBD Strategy, EA Pharma Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3520-852X","authenticated-orcid":false,"given":"Toshifumi","family":"Kajioka","sequence":"additional","affiliation":[{"name":"Department of IBD Strategy, EA Pharma Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2562-3308","authenticated-orcid":false,"given":"Masami","family":"Oiwa","sequence":"additional","affiliation":[{"name":"Department of IBD Strategy, EA Pharma Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3784-3203","authenticated-orcid":false,"given":"Tomoki","family":"Honjo","sequence":"additional","affiliation":[{"name":"Department of IBD Strategy, EA Pharma Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3357-7412","authenticated-orcid":false,"given":"Masaaki","family":"Higashikawa","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Development, Development Promotion & Data Science Group, EA Pharma Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2410-1032","authenticated-orcid":false,"given":"Masato","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of IBD Strategy, EA Pharma Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"issue":"6","key":"2025050802161914100_CIT0001","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","article-title":"Epidemiology and natural history of inflammatory bowel diseases","volume":"140","author":"Cosnes","year":"2011","journal-title":"Gastroenterology."},{"issue":"6","key":"2025050802161914100_CIT0002","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/ecco-jcc\/jjv052","article-title":"Internet-orientated assessment of QOL and actual treatment status in Japanese patients with inflammatory bowel disease: the 3I survey","volume":"9","author":"Matsumoto","year":"2015","journal-title":"J Crohns Colitis."},{"issue":"10114","key":"2025050802161914100_CIT0003","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"23","author":"Ng","year":"2017","journal-title":"Lancet."},{"issue":"12","key":"2025050802161914100_CIT0004","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s00535-019-01603-8","article-title":"Estimated prevalence of ulcerative colitis and Crohn\u2019s disease in Japan in 2014: an analysis of a nationwide survey","volume":"54","author":"Murakami","year":"2019","journal-title":"J Gastroenterol."},{"issue":"23","key":"2025050802161914100_CIT0005","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med."},{"issue":"2","key":"2025050802161914100_CIT0006","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology."},{"issue":"1","key":"2025050802161914100_CIT0007","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology."},{"issue":"13","key":"2025050802161914100_CIT0008","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."},{"issue":"8","key":"2025050802161914100_CIT0009","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med."},{"issue":"18","key":"2025050802161914100_CIT0010","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"issue":"10292","key":"2025050802161914100_CIT0011","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet."},{"issue":"10341","key":"2025050802161914100_CIT0012","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet."},{"issue":"14","key":"2025050802161914100_CIT0013","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med."},{"issue":"10383","key":"2025050802161914100_CIT0014","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet."},{"issue":"11","key":"2025050802161914100_CIT0015","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA."},{"issue":"7","key":"2025050802161914100_CIT0016","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology."},{"issue":"7","key":"2025050802161914100_CIT0017","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology."},{"issue":"1","key":"2025050802161914100_CIT0018","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"10","key":"2025050802161914100_CIT0019","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis."},{"issue":"3","key":"2025050802161914100_CIT0020","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1136\/gutjnl-2011-300988","article-title":"Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options","volume":"61","author":"Siegel","year":"2012","journal-title":"Gut."},{"issue":"5","key":"2025050802161914100_CIT0021","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1159\/000471795","article-title":"Shared decision making and treatment satisfaction in Japanese patients with inflammatory bowel disease","volume":"35","author":"Mahlich","year":"2017","journal-title":"Dig Dis."},{"issue":"10","key":"2025050802161914100_CIT0022","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/ibd\/izaa311","article-title":"Assessing patient decision-making on biologic and small-molecule therapies in inflammatory bowel diseases: insights from a conjoint analysis in the United States, Canada, and the United Kingdom","volume":"27","author":"Patel","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2025050802161914100_CIT0023","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae162","article-title":"Benefit-risk trade-offs and patient preferences for therapy selection in ulcerative colitis: a multicountry preference study","author":"Gisbert","year":"2024","journal-title":"Inflamm Bowel Dis."},{"issue":"7","key":"2025050802161914100_CIT0024","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/ibd\/izaa257","article-title":"Ulcerative Colitis Narrative global survey findings: communication gaps and agreements between patients and physicians","volume":"27","author":"Rubin","year":"2021","journal-title":"Inflamm Bowel Dis."},{"issue":"11","key":"2025050802161914100_CIT0025","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/ibd\/izab016","article-title":"Ulcerative Colitis Narrative Global survey findings: the impact of living with ulcerative colitis - a patients\u2019 and physicians\u2019 view","volume":"27","author":"Dubinsky","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2025050802161914100_CIT0026","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221095372","article-title":"Notable gaps between patients\u2019 and physicians\u2019 perspectives on communication and disease management in Japan: multifaceted ad hoc analyses of the global Ulcerative Colitis Narrative Survey for further optimal care","volume":"15","author":"Watanabe","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"issue":"9","key":"2025050802161914100_CIT0027","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1056\/NEJMp1109283","article-title":"Shared decision making--pinnacle of patient-centered care","volume":"366","author":"Barry","year":"2012","journal-title":"N Engl J Med."},{"key":"2025050802161914100_CIT0028","first-page":"1","article-title":"Choosing not to choose","volume":"64","author":"Sunstein","year":"2014","journal-title":"Duke Law J."},{"issue":"4","key":"2025050802161914100_CIT0029","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2307\/1600573","article-title":"Libertarian paternalism is not an oxymoron","volume":"70","author":"Sunstein","year":"2003","journal-title":"Univ Chicago Law Rev"},{"key":"2025050802161914100_CIT0030","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2147\/PPA.S289692","article-title":"Treatment satisfaction, patient preferences, and the impact of suboptimal disease control in a large international rheumatoid arthritis cohort: SENSE Study","volume":"15","author":"Taylor","year":"2021","journal-title":"Patient Prefer Adherence"},{"issue":"11","key":"2025050802161914100_CIT0031","doi-asserted-by":"publisher","first-page":"e0259389","DOI":"10.1371\/journal.pone.0259389","article-title":"Patient satisfaction, preferences, expectations, characteristics, and impact of suboptimal control of rheumatoid arthritis: a subgroup analysis of Japanese patients from a large international cohort study (SENSE)","volume":"16","author":"Kawahito","year":"2021","journal-title":"PLoS One."},{"issue":"1","key":"2025050802161914100_CIT0032","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.14309\/ajg.0000000000002263","article-title":"Comparative speed of early symptomatic remission with advanced therapies for moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"118","author":"Ahuja","year":"2023","journal-title":"Am J Gastroenterol."},{"issue":"1","key":"2025050802161914100_CIT0033","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","article-title":"Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis","volume":"17","author":"Hanauer","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2025050802161914100_CIT0034","doi-asserted-by":"publisher","first-page":"138","DOI":"10.14309\/ajg.0000000000001979","article-title":"Rapid and sustained symptom relief in patients with ulcerative colitis treated with filgotinib: data from the Phase 2b\/3 SELECTION Trial","volume":"118","author":"Danese","year":"2023","journal-title":"Am J Gastroenterol."},{"issue":"9","key":"2025050802161914100_CIT0035","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/j.cgh.2022.11.029","article-title":"Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment","volume":"21","author":"Loftus","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"11","key":"2025050802161914100_CIT0036","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/ecco-jcc\/jjae088","article-title":"Early and sustained symptom control with Mirikizumab in patients with ulcerative colitis in the Phase 3 LUCENT Program","volume":"18","author":"Danese","year":"2024","journal-title":"J Crohns Colitis."},{"issue":"9","key":"2025050802161914100_CIT0037","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1080\/17474124.2021.1898944","article-title":"Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration","volume":"15","author":"Denesh","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol."},{"issue":"4","key":"2025050802161914100_CIT0038","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/ibd\/izac119","article-title":"Comparative acceptability of therapeutic maintenance regimens in patients with inflammatory bowel disease: results from the Nationwide ACCEPT2 Study","volume":"29","author":"Buisson","year":"2023","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2025050802161914100_CIT0039","doi-asserted-by":"publisher","first-page":"ota9069","DOI":"10.1093\/crocol\/otad069","article-title":"Questionnaire survey for inflammatory bowel disease patients in Japan; a web-based Japan, Crohn\u2019s disease, ulcerative colitis, patients survey","volume":"5","author":"Matsumoto","year":"2023","journal-title":"Crohns Colitis."},{"issue":"1","key":"2025050802161914100_CIT0040","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000539738","article-title":"Patients\u2019 preference on advanced therapy and follow-up procedure for inflammatory bowel disease in Japan: a web-based 3A survey","volume":"9","author":"Morishita","year":"2024","journal-title":"Inflamm Intest Dis."},{"issue":"3","key":"2025050802161914100_CIT0041","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1159\/000528586","article-title":"Inflammatory bowel disease patients\u2019 preferences for subcutaneous versus intravenous therapies: a mixed-methods study","volume":"41","author":"van Deen","year":"2023","journal-title":"Dig Dis."},{"issue":"7","key":"2025050802161914100_CIT0042","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00535-009-0057-3","article-title":"Prevalence of ulcerative colitis and Crohn\u2019s disease in Japan","volume":"44","author":"Asakura","year":"2009","journal-title":"J Gastroenterol."},{"issue":"1","key":"2025050802161914100_CIT0043","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1053\/j.gastro.2013.04.007","article-title":"Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn\u2019s and colitis epidemiology study","volume":"145","author":"Ng","year":"2013","journal-title":"Gastroenterology."},{"issue":"1","key":"2025050802161914100_CIT0044","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41395-018-0233-2","article-title":"Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in Asia-Pacific","volume":"114","author":"Ng","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"3","key":"2025050802161914100_CIT0045","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/MIB.0000000000000313","article-title":"Incidence and natural course of inflammatory bowel disease in Korea, 2006\u20132012: a nationwide population based study","volume":"21","author":"Kim","year":"2015","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2025050802161914100_CIT0046","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.crohns.2013.09.012","article-title":"The accuracy of self-reported medical history: a preliminary analysis of the promise of internet-based research in inflammatory bowel diseases","volume":"8","author":"Kelstrup","year":"2014","journal-title":"J Crohns Colitis."},{"issue":"2","key":"2025050802161914100_CIT0047","doi-asserted-by":"publisher","first-page":"otaa030","DOI":"10.1093\/crocol\/otaa030","article-title":"Patients\u2019 preference of topical therapy for ulcerative colitis in Japan: a web-based 3T survey","volume":"2","author":"Yanai","year":"2020","journal-title":"Crohn\u2019s Colitis"}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otaf014\/62896825\/otaf014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/7\/2\/otaf014\/62896825\/otaf014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/7\/2\/otaf014\/62896825\/otaf014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T06:16:22Z","timestamp":1746684982000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otaf014\/8109143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otaf014","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,4]]},"article-number":"otaf014"}}